National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3
Awarded to Sanofi Aventis Ireland Ltd
Health Service Executive (HSE)(buyer)
- Published
- Published 1 October 2026
Tender documents
Skim pulls every file the buyer attaches to this process and extracts the requirements from it.
Documents as they publish
Specification, evaluation criteria, pricing schedules and every requirement — extracted, searchable and mapped to your response.
Overview
Contracting authority
- Health Service Executive (HSE)Procuring entity
2 awarded contracts
Kildare, Ireland
IE-NATIONAL: 0043024G
Authority website ↗
Find the key decision makers
The people who scope, score and sign this contract — names, roles and how to reach them.
What this covers
National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3
In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.
€1Won by Sanofi Aventis Ireland Ltd
Key details
- Country
- Ireland
- Status
- Contract signed
- Category
- Goods
- Estimated value
- €1
- Procedure
- Direct
- Published
- 1 October 2026
Award outcome
- Awarded value
- €1
- Award date
- 30 September 2026
- Sanofi Aventis Ireland Ltd
Contract ending soon? Skim tracks incumbents and flags recompetes early. Start for Free to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract
1 October 2026
More from Health Service Executive (HSE)
Other contracts from the same contracting authority. 2 awarded contracts on their hub.
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
How to win this tender
Skim reads the notice and every document attached to it, scores the fit against your company profile for a clear bid or no-bid call, then drafts each answer from your own evidence and past bids. You review, refine and submit — on time, with every requirement covered.
See exactly how Skim’s agents do this →
Comparing platforms? Skim is set against the alternatives for pre-tender intelligence, tender management software and bid management software.
Find tenders like this before your competitors do.
Skim scans every portal daily and scores each tender against your profile. Start for free and see the tenders you are missing.